Citations

Clear

3942 citation(s) found for "To, Van".

International Consensus Histopathological Criteria for Subtyping Idiopathic Multicentric Castleman Disease Based on Machine Learning Analysis
Nishimura, Midori Filiz , Haratake, Tomoka , Nishimura, Yoshito , Nishikori, Asami , Sumiyoshi, Remi , Ujiie, Hideki , Kawahara, Yuri, Ueki, Masao , Laczkó, Dorottya , Oksenhendler, Éric , Kawakami, Atsushi , Koga, Tomohiro , Oksenhendler, Eric , Fajgenbaum, David C , van Rhee, Frits , Sato, Yasuharu , Nishimura, Yoshito , Kawahara, Yuri, Fajgenbaum, David C. , Rhee, Frits van

Mayo Clinic

American Journal of Hematology | June 20, 2025 | Volume: 100 | Issue: 9 | Pages: 1502-1512

10.1002/ajh.27743 | PMID 40540535 Get It

ABSTRACTIdiopathic multicentric Castleman disease (iMCD) is a rare lymphoproliferative disorder classified into three recognized clinical subtypes—idiopathic plasmacytic lymphadenopathy (IPL), TAFRO, and NOS. Although clinical criteria are available for subtyping, diagnostically challenging cases with overlapping histopathological features highlight the need for an improved classification system integrating clinical and histopathological findings. We aimed to develop an objective histopathological subtyping system for iMCD that closely correlates with the clinical subtypes. Excisional lymph node specimens from 94 Japanese iMCD patients (54 IPL, 28 TAFRO, 12 NOS) were analyzed for five key histopathological parameters: germinal center (GC) status, plasmacytosis, vascularity, hemosiderin deposition, and “whirlpool” vessel formation in GC. Using hierarchical clustering, we visualized subgroups and developed a machine learning‐based decision tree to differentiate the clinical subtypes and validated it in an external cohort of 12 patients with iMCD. Hierarchical cluster analysis separated the IPL and TAFRO cases into mutually exclusive clusters, whereas the NOS cases were interspersed between them. Decision tree modeling identified plasmacytosis, vascularity, and whirlpool vessel formation as key features distinguishing IPL from TAFRO, achieving 91% and 92% accuracy in the training and test sets, respectively. External validation correctly classified all IPL and TAFRO cases, confirming the reproducibility of the system. Our histopathological classification system closely aligns with the clinical subtypes, offering a more precise approach to iMCD subtyping. It may enhance diagnostic accuracy, guide clinical decision‐making for predicting treatment response in challenging cases, and improve patient selection for future research. Further validation of its versatility and clinical utility is required.
A systematic review of interventions for persons living with dementia: The Geriatric ED Guidelines 2.0
Ragsdale, Luna , Seidenfeld, Justine , Oppen, James David van , Hooper, Carolina Diniz, Jaramillo, James A., Lo, Alexander X. , Hirata, Kaiho , Comasco, Lauren Cameron, Hogan, Teresita M., Liu, Shan W. , Group, Geriatric ED Guidelines Dementia Writing, Seidenfeld, Justine , van Oppen, James D , Hirata, Kaiho , Carpenter, Christopher R , Liu, Shan W , Lo, Alexander X , Lee, Sangil , Suh, Michelle , Lapointe‐Shaw, Lauren , Hooper, Carolina Diniz, Jaramillo, James, Wescott, Annie , Kennedy, Maura , Carpenter, Christopher R. , Group, Geriatric ED Guidelines Dementia Writing

Mayo Clinic

Academic Emergency Medicine | June 19, 2025 | Volume: 33 | Issue: 1 | Pages: No page available

10.1111/acem.70074 | PMID 40534401 Get It

Abstract Background The increasing prevalence of dementia poses significant challenges for emergency department (ED) care, as persons living with dementia (PLWD) more frequently experience adverse outcomes such as delirium, prolonged stays, and higher mortality rates. Despite advancements in care strategies, a critical gap remains in understanding how ED interventions impact outcomes in this vulnerable population. This systematic review aims to identify evidence‐based ED care interventions tailored to PLWD to improve outcomes. Methods A systematic review was conducted in Ovid MEDLINE, Cochrane Library (Wiley), Scopus (Elsevier), and ProQuest Dissertations & Theses Global through September 2024. The review protocol was registered on PROSPERO (CRD42024586555). Eligible studies included randomized controlled trials, observational studies, and quality improvement initiatives focused on ED interventions for PLWD. Data extraction and quality assessment were performed independently by two reviewers, with disagreements resolved through discussion. Outcomes included patient satisfaction, ED revisits, functional decline, and mortality. Results From 3305 screened studies, six met the inclusion criteria. Interventions included nonpharmacologic therapies (e.g., music and light therapy), specialized geriatric ED units, and assessment tools, such as for pain. Tailored interventions including geriatric emergency units and community paramedic care transitions were effective in reducing 30‐day ED revisits and hospitalizations. However, heterogeneity in study designs and outcomes precluded meta‐analysis. Risk of bias ranged from low to moderate. Conclusion This review underscores the urgent need for standardized and evidence‐based interventions in ED settings for PLWD. Approaches including multidisciplinary care models and nonpharmacologic therapies demonstrated potential for improving outcomes. Future research should prioritize consistent outcome measures, interdisciplinary collaboration, and person‐centered care strategies to enhance the quality and equity of ED services for PLWD.
Small and Stable Pancreatic Cysts Are Reassuring During Surveillance: Results From the PACYFIC Trial
Levink, Iris J. M. , Sprij, Marloes L. J. A. , Koopmann, Brechtje D.M. , Meziani, Jihane , Jaarsma, Sanne, Riet, Priscilla A. van , Overbeek, Kasper A. , Gorris, Myrte , Voermans, Rogier P. , Casadei, Riccardo , Hoogenboom, Sanne A. , Azopardi, Neville, Polkowski, Marcin , Honkoop, Pieter, Schoon, Erik J. , Venneman, Niels G. , Waaij, Laurens A. van der, Berkel, Anne‐Marie van, Rossi, Gemma , Bergmann, Jilling F., Pando, Elizabeth , Schwartz, Matthijs P. , Vilsteren, Frederike G.I. van , Hoge, Chantal , Smits, Marianne E., Soest, Ellert J. van, Vos, Patrick M., Steinhauser, Toon, Kouw, Eva, Tan, Adriaan C.I.T.L. , Czakó, László , Bruno, Marco J. , Cahen, Djuna L. , Group, PACYFIC‐Study Work, Quispel, Rutger , Verdonk, Robert C , Voermans, Rogier P , Hooft, Jeanin E. van , Casadei, Riccardo , Marco, Mariacristina Di , Wallace, Michael B. , Ahola, Reea , Carrara, Silvia , Bergmann, Jilling F., Beyer, Georg , Group, PACYFIC‐Study Work

Mayo Clinic

United European Gastroenterology Journal | June 18, 2025 | Volume: 13 | Issue: 6 | Pages: 971-981

10.1002/ueg2.70043 | PMID 40530613 Get It

ABSTRACTBackgroundPancreatic cysts are increasingly discovered on imaging studies performed for unrelated conditions. Currently, surveillance of these lesions poses a substantial burden on patients, and health care recourses. We hypothesized that individuals with small and stable cysts have a diminutive risk of progressing to high‐grade dysplasia (HGD) or pancreatic cancer (PC) that is similar to that in the general population.MethodsThis nested PACYFIC‐study is a collaboration among 44 centers in Europe and Northern‐America, and investigates the risk of HGD and PC for different cyst sizes and growth rates in participants without baseline worrisome features (WF) or high‐risk stigmata (HRS).ResultsOf the 2369 PACYFIC participants, 975 met the inclusion criteria, with a mean age of 67 years (SD 13) and 65% being female. Of these, 438 individuals (45%) had a baseline small cyst size (< 15 mm), and 885 (91%) individuals had a slow growth rate (< 2.5 mm/year). During a median follow‐up of 45 months (IQR 27), 20 individuals (2.1%) developed HGD, or PC. Individuals with small cysts had a 1.5‐fold lower risk of developing WF or HRS (hazard ratio [HR] 0.7 [0.5–1.0], p = 0.03) than those with larger cysts but a similar risk of developing HGD or PC (p > 0.05). Slow growth was protective against the development of WF or HRS (HR 0.4 [0.2–0.6], p < 0.001) and HGD or PC (HR 0.04 [95% CI 0.02–0.12], p < 0.001). Individuals with small, stable sized cysts without baseline WF or HRS did not have a higher risk of HGD or PC than the general population (standardized incidence ratio [SIR] 1.13 [95% CI 0.01–6.30]).ConclusionCyst size < 15 mm and growth rate < 2.5 mm/year appear to be “reassuring” features associated with a negligible risk of developing WF or HRS and HGD or PC. For cysts with these characteristics—and without baseline WF or HRS—less intensive surveillance (than currently recommended) or even cessation may be appropriate.
Immune Subtyping Identifies Patients With Hormone Receptor–Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial
Wolf, Denise M. , Yau, Christina , Glas, Annuska M. , Barcaru, Andrei, Kuilman, Midas M. , Swigart, Lamorna Brown , Hirst, Gillian L. , Basu, A. , Magbanua, Mark Jesus M. , Sayaman, Rosalyn W. , Huppert, Laura A. , Investigators, I-SPY2, Borowsky, Alexander D. , Pohlmann, Paula R. , Clark, Amy S. , Yee, Douglas , Perlmutter, Jane , Petricoin, Emanuel F. , Chien, A. Jo , Stringer-Reasor, Erica , Liu, Minetta C. , Nanda, Rita , Veer, Laura van ‘t , Melisko, Michelle , Albain, Kathy S. , Robinson, Patricia A. , Lo, Simon S. , Potter, David J. , Beckwith, Heather , Haddad, Tufia C. , Kemmer, Kathleen, Lu, Janice , Williams, Nicole , Ellis, Erin D. , Sanford, Amy, Sanft, Tara, Viscusi, Rebecca K., Arora, Mili, Northfelt, Donald W. , Haley, Barbara , Yung, Rachel L. , Mayer, Ingrid, Khan, Qamar J. , Edmiston, Kirsten K., Glas, Annuska , Mittempergher, Lorenza , Brown-Swigart, Lamorna , Hirst, Gillian L , Basu, Amrita , Magbanua, Mark J M , Sayaman, Rosalyn , Huppert, Laura , Delson, Amy , Symmans, W Fraser , Pohlmann, Paula , Rugo, Hope S , Clark, Amy S , Yee, Douglas , DeMichele, Angela , Petricoin, Emmanuel F , Chien, Jo , Stringer-Reasor, Erica , Shatsky, Rebecca , Liu, Minetta , Soliman, Hatem Hussein , Isaacs, Claudine , Nanda, Rita , Hylton, Nola M. , Pusztai, Lajos , Esserman, Laura J , Veer, Laura J. van’t , Campbell, Michael, Investigators, I-SPY2, Symmans, W. Fraser , Rugo, Hope S. , DeMichele, Angela , Shatsky, Rebecca , Han, Hyo S , Isaacs, Claudine , Pusztai, Lajos , Esserman, Laura J. , Mukhtar, Rita A. , Wallace, Anne M. , Yeung, Kay T. , Olopade, Olufunmilayo I. , Potter, David, Blaes, Anne , Boughey, Judy C. , Elias, Anthony , Mitri, Zahi Ibrahim , Lang, Julie E. , Thomas, Alexandra , Trivedi, Meghna S. , Hershman, Dawn L. , Meisel, Jane Lowe , Kalinsky, Kevin M. , Vaklavas, Christos , Sanft, Tara , Arora, Mili, Falkson, Carla I. , Murthy, Rashmi Krishna

Mayo Clinic

JCO Precision Oncology | June 17, 2025 | Volume: No volume available | Issue: 9 | Pages: No page available

10.1200/po-24-00776 | PMID 40526879 Get It

PURPOSE Neoadjuvant immunotherapy (IO) has become the standard of care for early-stage triple-negative breast cancer (TNBC), but not yet for other subtypes. We previously developed a clinical-grade mRNA-based immune classifier (ImPrint) predicting response to IO that is now being used in I-SPY2.2 as part of the response predictive subtypes. We report the performance of ImPrint in hormone receptor–positive and human epidermal growth factor receptor 2–negative (HR+HER2–) patients from five IO arms. METHODS A total of 204 HR+HER2– (MammaPrint high-risk) patients from five IO arms (anti–PD-1, anti–PD-L1/poly [ADP-ribose] polymerase inhibitor combination, anti–PD-1/toll-like receptor 9 dual-IO combination, and anti–PD-1 ± lymphocyte activation gene 3 dual-IO combination) and 191 patients from the chemotherapy-only control arm were included in this analysis. Patients were classified as ImPrint+ (likely sensitive) versus ImPrint– (likely resistant), using pretreatment mRNA. Performance of ImPrint for predicting pathologic complete response (pCR) to IO-containing arms was characterized and compared with tumor grade (III), MammaPrint (ultra) High2 risk (MP2), and estrogen receptor (ER)-low (ER ≤ 10%). RESULTS Overall, the pCR rate across the five IO arms was 33%. 26% of HR+HER2– patients were ImPrint+, and pCR rates with IO were 75% in ImPrint+ versus 17% in ImPrint–, with the highest pCR rate >90% in a dual-IO arm. In the control arm, pCR rates were 33% in ImPrint+ and 8% in ImPrint–. Tumor grade (III), MP2, and ER-low showed pCR rates in IO of 45%, 56%, and 63%, respectively, with lower pCR odds ratios (OR < 7.5) compared with ImPrint (OR = 14.5). CONCLUSION Using an accurate selection strategy, HR+HER2– patients could achieve pCR rates similar to what is seen with best neoadjuvant therapies in TNBC and HER2+ (ie, pCR rate >65%-70%). ImPrint, an Food and Drug Administration IDE-enabled assay, may represent a way to identify HR+HER2– patients for IO that best balances likely benefit versus risk of serious immune-related adverse events.
Frequency and Clinical Outcomes Associated With Tau Positron Emission Tomography Positivity
Raghavan, Sheelakumari, Costoya‐Sánchez, Alejandro , Mainta, Ismini , Rodríguez-Fonseca, Omar Darío, Perissinotti, Andrés , Gu, Yuna , Yun, Jihwan, Peretti, Débora Elisa , Aguiar, Pablo , Bischof, Gérard N. , Seo, Sang Won , Villeneuve, Sylvia , O’Brien, John T. , Jagust, William, Frisoni, Giovanni B. , Soleimani‐Meigooni, David N. , Carrillo, Marı́a C., Joie, Renaud La , Rabinovici, Gil D. , Apostolova, Liana G. , Pontecorvo, Michael J. , Johnson, Keith A. , Weiner, Michael W. , Petersen, Ronald C., Jack, Clifford R. , Schöll, Michael , Labonté, Anne , Faubert, Anne‐Marie, Mathieu, Axel, Madjar, Cécile , Carrier, Charles Edouard, Kazazian, Christina, Lepage, Claude, Maillet, David , Michaud, Diane, Couture, Doris, Dea, Doris, Courcot, Blandine, Debacker, Clément , Fontaine, David, Knopman, David S. , Multhaup, Gerhard, Maltais, Jean‐Robert, Breitner, John C.S. , Poirier, Judes, Cheewakriengkrai, Laksanun, Sager, Mark A., Dauar‐Tedeschi, Marina, Rajah, Natasha, Aisen, Paul, Toussaint, Paule‐Joanne , Pierre, Bellec, Kostopoulos, Penelope, Étienne, Pierre , Tariot, Pierre N. , Orban, Pierre , Hoge, Rick, Thomas, Ronald J. , Gauthier, Serge , Craft, Suzanne , Montine, Thomas J. , Nair, Vasavan, Bohbot, Véronique D. , Venugopalan, Vinod, Ituria‐Medina, Yasser, Khachaturian, Zaven S., Teigner, Eduard, Anthal, Elena, Yu, Elsa, Ferdinand, Fabiola, Pogossova, Galina, Mayrand, Ginette, Duclair, Guerda, Gagné, Guylaine, Newbold‐Fox, Holly, Leppert, Illana, Tremblay‐Mercier, Jennifer , Frenette, Joanne, Frappier, Josée, Kat, Justin, Miron, Justin , Wan, Karen, Mahar, Laura, Carmo, Leopoldina, Théroux, Louise, Dufour, Marianne, Lafaille‐Magnan, Marie‐Élyse, Savard, Mélissa, Tuwaig, Miranda, Petkova, Mirela, Rioux, Pierre, Meyer, P.T., El‐Khoury, Rana, Gordon, Renee, Giles, Renuka, Das, Samir, Wang, Seqian, Tabrizi, Shirin , Mathotaarachchi, Sulantha , Dubuc, Sylvie, Lee, Tanya , Beaudry, Thomas, Gervais, Valérie, Pagé, Véronique, Desautels, René, Benbouhoud, Fatiha, Saint‐Fort, Eunice Farah, Verfaillie, Sander C.J. , Farzin, Sarah , Salaciak, Alyssa , Tullo, Stéphanie , Daoust, Leslie‐Ann, Köbe, Theresa , McSweeney, Melissa, Nilsson, Nathalie , Pishnamazi, Morteza, Bedetti, Christophe , Hudon, Louise, Greco, Claudia, Chapleau, Marianne , St‐Onge, Frédéric , Boutin, Sophie , Geddes, Maiya R. , Ducharme, Simon , Jean, Gabriel, Sylvain, Elisabeth, Élie, Marie‐Josee, Leblond‐Baccichet, Gloria, Soucy, Jean‐Paul , Ozlen, Hazal , Bailly, Julie, Mohammediyan, Béry, Chen, Yalin , Remz, Jordana, Rentz, Dorene M., Amariglio, Rebecca E. , Blacker, Deborah , Chhatwal, Jasmeer P. , Dickerson, Brad C., Donovan, Nancy J. , Farrell, Michelle E. , Gómez, Cristina Lois, Marshall, Gad A. , Oaoo, Kate, Price, Julie, Prokopiou, Prokopis C. , Reynolds, Gretchen , Skylar-Scott, Irina A., Vila‐Castelar, Clara , Yang, Hyun‐Sik , Trojanowki, John Q., Green, Robert C, Perrin, Richard J. , Shaw, Leslie M. , Potter, William Z. , Bernard, Marie , Jackson, Jonathan, Masliah, Eliezer , Masterman, Donna, Okonkwo, Ozioma, Ryan, Laurie, Silverberg, Nina, Fleisher, Adam , Fockler, Juliet , Conti, Cat, Jin, Chengshi , Nosheny, Rachel L. , Ashford, Mariam, Flenniken, Derek , Kormos, Adrienne, Montine, Tom, Rafii, Michael, Raman, Rema , Gessert, Devon, Salazar, Jennifer, Zimmerman, Caileigh, Cabrera, Yuliana, Walter, Sarah , Miller, Garrett, Coker, Godfrey, Clanton, Taylor, Hergesheimer, Lindsey, Smith, Stephanie , Adegoke, Olusegun, Mahboubi, Payam, Moore, Shelley, Pizzola, Jeremy, Shaffer, Elizabeth , Harvey, Danielle, Forghanian-Arani, Arvin, Borowski, Bret, Ward, Chad, Gunter, Jeff, Kantarci, Kejal, Thompson, Paul , Jahanshad, Neda , DeCarli, Charles , Knaack, Alexander , Fletcher, Evan, Chen, Stephanie R, Choe, Mark, Crawford, Karen , Yuschkevich, Paul A, Reiman, Eric M. , Mathis, Chet, Landau, Susan , Cairns, Nigel J. , Householder, Erin, Franklin, Erin , Bernhardt, Haley, Taylor‐Reinwald, Lisa, Korecka, Magdalena , Figurski, Michal, Neu, Scott, Nho, Kwangsik, Foroud, Tatiana M., Faber, Kelley , Wilmes, Kristi, Thal, Leon J., Dage, Jeffrey L. , Eloyan, Ani , Hammers, Dustin B. , Kirby, Kala, Kramer, Joel, Legarde, Julien, Murray, Melissa E., Newell, Kathy L. , Taurone, Alexander, Thangarajah, Maryanne, Touroutoglou, Alexandra , Clark, David , Day, Gregory S, Duara, Ranjan , Graff-Radford, Neill R, Grant, Ian , Masdeu, Joseph C. , Mendez, Mario F. , Onyike, Chiadi U. , Riddle, Meghan , Rogalskı, Emily , Salloway, Steven, Sha, Sharon J. , Carrillo, María C. , O'Brien, John Tiernan , Jack, Clifford R , Schöll, Michael , La Joie, Renaud , Rabinovici, Gil D , Dage, Jeffrey L , Rial, Alexis Moscoso , Heeman, Fiona , Raghavan, Sheelakumari , Essen, Martijn van , Camacho, Valle , Silva‐Rodríguez, Jesús , Ribaldi, Federica , Coomans, Emma M. , Brum, Wagner Scheeren , Grothe, Michel J. , Drzezga, Alexander E. , Malpetti, Maura , Rowe, James B. , Giessen, Elsmarieke van de , Ossenkoppele, Rik , Smith, Ruben , Hansson, Oskar , Garibotto, Valentina , Dickerson, Bradford Clark , LaMontagne, Pamela , Sperling, Reisa Anne , Vemuri, Prashanthi , Tam, Angela , Binette, Alexa Pichet , Dansereau, Christian , Picard, Cynthia , Michaud, Diane, Couture, Doris, Cuello, A. Claudio , Barkun, Alan , Evans, Alan Charles , Tardif, Christine Lucas , Knopman, David S. , Near, Jamie , Leoutsakos, Jeannie‐Marie , Brandt, Jason , Pruessner, Jens C. , Morris, John C. , Collins, D. Louis , Chakravarty, M. Mallar , Eisenberg, Mark Jeffrey , Rajah, Maria Natasha , Rosa-Neto, Pedro , Bellec, Pierre , Thomas, Ronald, Fonov, Vladimir , Vallee, Isabelle, Vogel, Jacob W. , Dadar, Mahsa , Appleby, Melissa , Meyer, Pierre‐François, Gonneaud, Julie , Pascoal, Tharick Ali , Vachon‐Presseau, Étienne , Spreng, R. Nathan , Rentz, Dorene M. , Buckley, Rachel F. , Gagliardi, Geoffroy Pierre , Gatchel, Jennifer R. , Guzmán‐Vélez, Edmarie , Jacobs, Heidi I.L. , Jutten, Roos J. , Pardilla‐Delgado, Enmanuelle , Price, Julie C. , Quiroz, Yakeel T. , Schultz, Aaron P. , Schultz, Stephanie A. , Sepulcre, Jorge , Vannini, Patrizia , Toga, Arthur W. , Beckett, Laurel , Saykin, Andrew J. , Potter, William, Barnes, Lisa L. , Gonzalez, Hector, Ho, Carole , Hsiao, John , Jackson, Jonathan , Veitch, Dallas P. , Neuhaus, John M , Rafii, Michael S. , Jimenez‐Maggiora, Gustavo Adolfo , Donohue, Michael , Arani, Arvin , Schwarz, Christopher G. , Jones, David T. , Kantarci, Kejal , Senjem, Matthew L. , Reid, Robert I. , Fox, Nick C. , Malone, Ian B. , Thomopoulos, Sophia I. , Nir, Talia M. , Tosun, Duygu , Das, Sandhitsu R. , Koeppe, Robert A. , Chen, Kewei , Risacher, Shannon L. , Shen, Li , Nudelman, Kelly , Ghetti, Bernardino , Grinberg, Lea T. , Hammers, Dustin B , Kirby, Kala, Kukull, Walter A. , Murray, Melissa E. , Polsinelli, Angelina J. , Atri, Alireza , Duara, Ranjan , Graff‐Radford, Neill R. , Honig, Lawrence S. , Johnson, Erik C. B. , Masdeu, Joseph C , Musiek, Erik , Salloway, Steve , Turner, Raymond Scott , Wingo, Thomas S , Wolk, S. J. , Womack, Kyle

Mayo Clinic

JAMA | June 16, 2025 | Volume: 334 | Issue: 3 | Pages: 229

10.1001/jama.2025.7817 | PMID 40522652 Get It

Importance Tau positron emission tomography (PET) allows in vivo detection of neurofibrillary tangles, a core neuropathologic feature of Alzheimer disease (AD). Objective To provide estimates of the frequency of tau PET positivity and its associated risk of clinical outcomes. Design, Setting, and Participants Longitudinal study using data pooled from 21 cohorts, comprising a convenience sample of 6514 participants from 13 countries, collected between January 2013 and June 2024. Cognitively unimpaired individuals and patients with a clinical diagnosis of mild cognitive impairment (MCI), AD dementia, or other neurodegenerative disorders were included. Exposures Tau PET with flortaucipir F 18, amyloid-β (Aβ) PET, and clinical examinations. Tau PET scans were visually rated as positive according to a US Food and Drug Administration– and European Medicines Agency–approved method, designed to indicate the presence of advanced neurofibrillary tangle pathology (Braak stages V-VI). Main Outcomes and Measures Frequency of tau PET positivity and absolute risk of clinical progression (eg, progression to MCI or dementia). Results Among the 6514 participants (mean age, 69.5 years; 50.5% female), median follow-up time ranged from 1.5 to 4.0 years. Of 3487 cognitively unimpaired participants, 349 (9.8%) were tau PET positive; the estimated frequency of tau PET positivity was less than 1% in those aged younger than 50 years, and increased from 3% (95% CI, 2%-4%) at 60 years to 19% (95% CI, 16%-24%) at 90 years. Tau PET positivity frequency estimates increased across MCI and AD dementia clinical diagnoses (43% [95% CI, 41%-46%] and 79% [95% CI, 77%-82%] at 75 years, respectively). Most tau PET–positive individuals (92%) were also Aβ PET positive. Cognitively unimpaired participants who were positive for both Aβ PET and tau PET had a higher absolute risk of progression to MCI or dementia over the following 5 years (57% [95% CI, 45%-71%]) compared with both Aβ PET–positive/tau PET–negative (17% [95% CI, 13%-22%]) and Aβ PET–negative/tau PET–negative (6% [95% CI, 5%-8%]) individuals. Among participants with MCI at the time of the tau PET scan, an Aβ PET–positive/tau PET–positive profile was associated with a 5-year absolute risk of progression to dementia of 70% (95% CI, 59%-81%). Conclusions and Relevance In a large convenience sample, a positive tau PET scan occurred at a nonnegligible rate among cognitively unimpaired individuals, and the combination of Aβ PET positivity and tau PET positivity was associated with a high risk of clinical progression in both preclinical and symptomatic stages of AD. These findings underscore the potential of tau PET as a biomarker for staging AD pathology.
Preanalytical variables and analytes in liquid biopsy approach for brain tumors: A comprehensive review and recommendations from the RANO Group and the Brain Liquid Biopsy Consortium
Bettegowda, Chetan , Noushmehr, Houtan , Affinito, Alessandra , Ahluwalia, Manmeet S. , Ansorge, Olaf , Ayasoufi, Katayoun , Bagley, Stephen , Barnholtz‐Sloan, Jill S. , Brandsma, Dieta , Brodie, Chaya , Castro, Ana Valeria , Chang, Susan M. , Daher, Ahmad , Datta, Vineet , French, Pim J. , Golebiewska, Anna , Holdhoff, Matthias , LeBlang, Suzanne , Melin, Beatrice , Moulière, Florent , O’Leary, Claire , Robinson, Stephen , Sol, Nik , Vogelbaum, Michael A. , Walbert, Tobias , Watts, Colin , Wen, Patrick Y. , Wykes, Victoria , Yip, Stephen , Short, Susan , Barnholtz-Sloan, Jill S , Best, Myron , Brandsma, Dieta , Brüning-Richardson, Anke , Chang, Susan Marina , Condorelli, Gerolama , Daher, Ahmad , de Groot, John , French, Pim J , Galanis, Evanthia , Golebiewska, Anna , Hamerlik, Petra , Hanemann, C Oliver , Holdhoff, Matthias , Huse, Jason T. , Khasraw, Mustafa , LeBlang, Suzanne , Melin, Beatrice , Rominiyi, Ola , Roncaroli, F , Rudà, Roberta , Sol, Nik , van den Bent, Martin J , Walbert, Tobias , Watts, Colin , Weiss, Tobias , Weller, Michael , Wykes, Victoria , Yip, Stephen , Short, Susan C , Soffietti, Riccardo , Noushmehr, Houtan , Ayasoufi, Katayoun , Ahluwalia, Manmeet S , Bettegowda, Chetan , Groot, John de , Galanis, Evanthia , Hamerlik, Petra , Hanemann, C. Oliver , Khasraw, Mustafa , Rak, Janusz , Ray, Amitava, Roncaroli, Federico , Seoane, Joan , Bent, Martin J. van den , Wen, Patrick Yung , Soffietti, Riccardo

Mayo Clinic

Neuro-Oncology | June 16, 2025 | Volume: 27 | Issue: 10 | Pages: 2496-2513

10.1093/neuonc/noaf140 | PMID 40884415 Get It

Abstract This review explores the pivotal role of preanalytical variables in bringing liquid biopsy approaches into the clinic for brain tumors. Preanalytical variables encompass a range of critical issues, from blood sample collection and handling to the impact of tumor heterogeneity and patient-specific factors. These variables introduce challenges such as false positives, false negatives, and variability in the analysis of tumor signals, which can hinder the diagnostic and prognostic utility of liquid biopsies. Understanding the nuances of preanalytical variables is essential for the successful implementation of liquid biopsy in clinical settings. This paper delves into strategies aimed at mitigating the influence of preanalytical variables by emphasizing the importance of standardized sample collection protocols, optimized sample processing and storage, quality control measures, and the integration of multiple liquid biopsy modalities.
557 | EVALUATING UPTAKE OF TARGETED AGENTS BY RACE/ETHNICITY IN PATIENTS RECEIVING FIRST‐LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA
Kittai, Adam S. , Hampel, Paul J. , Fu, Qiang , Sun, Steven , Beuge, Derrick van, Maglinte, Gregory A. , Rhodes, Joanna , Wang, X., Seymour, Erlene Kuizon , Barrientos, Jacqueline C.

Mayo Clinic

Hematological Oncology | June 15, 2025 | Volume: 43 | Issue: S3 | Pages: No page available

10.1002/hon.70096_557 Get It

611 | TUMOR EVOLUTION AND IMMUNE MICROENVIRONMENT DYNAMICS IN PRIMARY AND RELAPSED MANTLE CELL LYMPHOMA
Wan, Hui , Ren, Weicheng , Yang, Mao , Wasik, Agata M. , Nie, M., Yang, Chuan , Ansell, Steven M., Liu, D. , Sander, Birgitta , Li, Xiangchun , Du, Lei , Campos‐Mata, Leire de , Nie, M., Ye, Xiaojing , Yang, Zhi Ping , Burg, Mirjam van der , Wu, Kui , Pan‐Hammarström, Qiang

Mayo Clinic

Hematological Oncology | June 15, 2025 | Volume: 43 | Issue: S3 | Pages: No page available

10.1002/hon.70096_611 Get It

The Importance of Impedance: A Case of Responsive Neurostimulation Failure Characterized by Concurrent Stereoelectroencephalography
Palit, Sandhya R. , Gregg, Nicholas M. , Gregg, Nicholas M , Hines, Kevin , Gompel, Jamie J. Van , Lundstrom, Brian N.

Mayo Clinic

Journal of Clinical Neurophysiology | June 13, 2025 | Volume: 42 | Issue: 7 | Pages: 660-664

10.1097/wnp.0000000000001176 | PMID 40512604 Get It

Summary: Epilepsy neuromodulation treatment failure is a significant challenge, with multiple possible causes. The responsive neurostimulation (RNS) system delivers stimulation from a single current source, and the relative flow of the electrical current through each stimulating contact is inversely proportional to the relative impedance of each contact. Current shunting through low-impedance contacts (i.e., intraventricular contacts) can divert therapy away from the intended targets and may be a cause of treatment failure. We present a case of a patient with bitemporal epilepsy and bitemporal encephaloceles, with poor response to bilateral mesial temporal RNS, who completed stereotactic EEG (sEEG) monitoring to investigate the possible causes of treatment failure. The sEEG was safely completed without damaging the RNS device. The sEEG recorded independent bitemporal interictal epileptiform discharges and seizures, which did not arise from sampled encephalocele regions. The sEEG-recorded RNS stimulation artifact was reduced in the left mesial temporal region relative to the right, which suggested potential current shunting through the right-sided contacts. Impedance measurements confirmed several low-impedance contacts from the right lead, with associated intraventricular position on imaging. At last follow up, 161 days after replacement of the right lead, the patient experienced an additional 58% reduction in seizure burden. Effective therapy delivery by single-current-source neurostimulation systems, such as RNS, critically depends on relative electrode impedances. Current shunting through low-impedance contacts is an underappreciated potential cause of treatment failure. Routine impedance assessments and individualized stimulation programs are recommended to avoid unintended current diversion. Concurrent sEEG monitoring and active RNS are feasible and can characterize stimulation effects.